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Clinical and Population Studies
Familial Combined Hyperlipidemia Is Associated With
Alterations in the Cholesterol Synthesis Pathway
Thomas M. van Himbergen, Seiko Otokozawa, Nirupa R. Matthan, Ernst J. Schaefer,
Aaron Buchsbaum, Masumi Ai, Lambertus J.H. van Tits, Jacqueline de Graaf, Anton F.H. Stalenhoef
Objectives—Familial combined hyperlipidemia (FCH) is a common familial lipid disorder characterized by increases in
plasma total cholesterol, triglyceride, and apolipoprotein B-100 levels. In light of prior metabolic and genetic research,
our purpose was to ascertain whether FCH cases had significant abnormalities of plasma markers of cholesterol
synthesis and absorption as compared to unaffected kindred members.
Methods and Results—Plasma levels of squalene, desmosterol, and lathosterol (cholesterol synthesis markers) and
campesterol, sitosterol, and cholestanol (cholesterol absorption markers) were measured by gas-liquid chromatography
in 103 FCH patients and 240 normolipidemic relatives (NLR). Squalene, desmosterol, and lathosterol levels were 6%
(0.078), 31%, (P0.001) and 51% (P0.001) higher in FCH as compared to NLR, and these differences were especially
pronounced in women. An interaction with obesity was also noted for a subset of these markers. We did not observe
any apparent differences for the cholesterol absorption markers among FCH patients and NLR.
Conclusions—Our data indicate that both men and women with FCH have alterations in the cholesterol synthesis pathway,
resulting in 51% higher levels of lathosterol (and additionally desmosterol in women). Plasma levels of the cholesterol
precursor sterol squalene were only slightly increased (6%), suggesting enhanced conversion of squalene to lathosterol
in this disorder. (Arterioscler Thromb Vasc Biol. 2010;30:113-120.)
Key words: cholesterol  lipids  sterols  familial combined hyperlipidemia
Familial combined hyperlipidemia (FCH) is a commongenetic lipid disorder. Affected subjects characteristically
have elevated levels of plasma total cholesterol, triglycerides,
and apolipoprotein (apo) B, and are more prone to develop
premature cardiovascular disease (CVD).1,2 The prevalence
of FCH in the general population has been reported to be up
to about 6%,3 whereas in families with premature coronary
heart disease prevalence rates of 15% to 20% have been
reported.1,2,4,5
The pathophysiological mechanism underlying FCH is
believed to be hepatic overproduction of apoB-100 con-
taining lipoprotein particles (ie, VLDL and LDL), result-
ing in increased plasma total cholesterol, triglycerides, and
apoB levels.6 – 8 In addition, lower levels of HDL choles-
terol and increased amounts of small dense LDL (sdLDL)
and remnant lipoprotein particles have been observed in
patients with FCH.2,9 –14
The heterogeneous lipid profile indicates that FCH is a
multifactorial disease in which several genes affect the
lipid and lipoprotein metabolism. To date, the most impor-
tant genetic data has been generated by 2 genome-wide
scan studies in Finnish and Dutch populations, respec-
tively, showing associations of the FCH phenotype with
regions on chromosome 1 and 11.15,16 When the same
diagnostic criteria were used, both studies linked FCH to
the 1q21–23 genomic region which codes for the upstream
transcription factor 1 (USF1) gene.17 USF1, however,
transcribes a wide array of genes which play a role in the
lipid and glucose metabolism,17 making it a complex task
to identify the exact genes involved in FCH.
Previously it has been postulated that the apoB secretory
rate is related to cholesterol and cholesterol ester mass,18
and studies show that there is a clear link between fatty
acid flux to the liver and increased cholesterol synthe-
sis.19,20 The purpose of the current study was to investigate
the underlying mechanisms leading to the lipid elevations
seen in FCH patients by measuring plasma markers of
cholesterol synthesis and absorption. Total body choles-
terol pools represent a balance between endogenous syn-
thesis of cholesterol on the one hand and dietary absorp-
tion of cholesterol on the other.21 It has been documented
using formal cholesterol balance studies, that plasma level
of the cholesterol precursors squalene, lathosterol, and
desmosterol serve as markers of cholesterol synthesis,22,23
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whereas the plant sterols campesterol and sitosterol (both
derived from the diet), and the bile acid residue cholesta-
nol, are all absorbed in very low quantities in the intestine
and their plasma levels have been demonstrated to serve
as markers of fractional cholesterol absorption.23 In support,
treatment with cholesterol synthesis and absorption inhibiters
(ie, statins and ezetemibe) not only lower total cholesterol
levels, they also specifically lower plasma levels of these
synthesis and absorption markers, respectively.24,25
For the current study we measured squalene, desmos-
terol, lathosterol (markers of synthesis) and campesterol,
and sitosterol and cholestanol (markers of absorption) in a
population of FCH patients and their normolipidemic
relatives (NLR). In addition, we also performed an exten-
sive characterization of the lipid profiles in these FCH
families, measuring total cholesterol, triglycerides,
LDL-C, HDL-C and VLDL-C, sdLDL-C, total apoB lev-
els, apoB48 particles, and remnant lipoprotein cholesterol
(RLPC), of which apoB-48 is a specific marker of intesti-
nal lipid transport.
Methods
Study Population
The study population consisted of 343 subjects, 103 FCH patients
and 240 NLR, from 32 well-defined FCH families.26 The diag-
nosis of FCH was based on a previously established nomogram.27
Briefly, plasma triglycerides and total cholesterol levels, adjusted
for age and gender, and absolute apoB levels were included in a
nomogram to calculate the likelihood of having FCH. A subject
was defined as being affected with FCH if the probability was
above 60%, provided that the diagnostic phenotype was also
present in at least 1 first-degree relative and premature CVD (ie,
before the age of 60) was present in at least 1 individual in the
family. Families were excluded when a secondary cause of the
hyperlipidemia was diagnosed in the proband (ie, diabetes mel-
litus, hypothyroidism, and hepatic or renal impairment). Before
the start of the study all participants withdrew from using
lipid-lowering medication for at least 4 weeks. Blood was drawn
after an overnight fast for laboratory analyses and the isolation of
DNA. The ethics committee of the Radboud University Nijmegen
Medical Center approved the study protocol and all subjects gave
informed consent.
Laboratory Measurements
Plasma total cholesterol, triglycerides, LDL-C, VLDL-C, HDL-C,
apoB, and glucose concentrations in all subjects were determined
using routine laboratory procedures as previously described.28
Insulin was measured directly by an immunoassay obtained from
the Otsuka Corporation.29 Small dense (sd) LDL-C was measured
using kits obtained from the Denka Seiken Company.30 RLPC
was measured using kits obtained from the Kyowa Medex
Corporation,31 and plasma apoB48 was measured by an enzyme
linked immunoassay obtained from the Shibayagi Company as
previously described.32 All assays had within and between run
coefficients of variation of less than 5%, and the nonroutine
assays were only performed on a subset of subjects because of
limited sample availability (see footnote to Table 1).
Measurements of Plasma Sterols
Plasma concentrations of squalene, lathosterol, desmosterol, campes-
terol, sitosterol and cholestanol were measured using gas-liquid
chromatography according to methods previously described in all
subjects and were expressed as mol/L as well as normalized to
102 mmol/mol total cholesterol.33
Statistical Analyses
All continuous variables were checked for their distribution and
expressed as meansSD, or in the case of nonlinear distributions,
Table 1. Study Characteristics of the Normolipidemic Relatives (NLR) and Patients With Familial Combined Hyperlipidemia (FCH) in
the Population at Large and by Gender
All Subjects Men Women
NLR FCH % Difference NLR FCH % Difference NLR FCH % Difference
n 240 103 … 117 45 … 123 58 …
Age, y 44 (15) 51 (15) 16* 44 (14) 52 (12) 18* 44 (15) 50 (17) 14‡
BMI, kg/m2 25 (3) 29 (4) 16* 25.5 (3.3) 28.8 (3.5) 13* 24.8 (3.5) 28.5 (4.6) 15*
WHR 0.87 (0.08) 0.91 (0.08) 5† 0.92 (0.07) 0.97 (0.04) 5* 0.83 (0.06) 0.86 (0.06) 4‡
Glucose, mmol/L 4.8 (4.5, 5.2) 5.1 (4.6, 5.6) 6† 4.9 (4.6, 5.3) 5.4 (5.0, 5.9) 10‡ 4.6 (4.4, 5.0) 4.9 (4.4, 5.3) 7‡
Insulin, U/mL 5.9 (4.1, 8.1) 8.8 (6.8, 12.4) 49* 6.3 (3.9, 8.3) 8.7 (6.1, 9.5) 38† 5.8 (4.2, 7.8) 8.9 (7.4, 13.0) 53*
Triglycerides, mmol/L 1.2 (0.9, 1.6) 2.9 (2.0, 4.1) 142* 1.4 (1.0, 1.8) 3.4 (2.7, 4.8) 143* 1.1 (0.8, 1.3) 2.5 (1.7, 3.2) 127*
Total cholesterol 5.2 (1.0) 6.9 (1.2) 33* 5.4 (0.9) 7.0 (1.2) 30* 5.1 (0.9) 6.8 (1.2) 33*
HDL-C, mmol/L 1.3 (0.3) 1.1 (0.3) 15* 1.2 (0.3) 1.0 (0.2) 17* 1.4 (0.3) 1.3 (0.2) 7*
LDL-C, mmol/L 3.5 (0.9) 4.2 (1.2) 20* 3.7 (0.9) 3.9 (1.3) 5 3.3 (0.9) 4.4 (1.1) 33*
Non HDL-C, mmol/L 3.9 (0.9) 5.7 (1.2) 46* 4.2 (0.9) 6.0 (1.1) 43* 3.7 (0.9) 5.5 (1.2) 49*
VLDL-C, mmol/L 0.4 (0.2, 0.6) 1.1 (0.7, 1.9) 175* 0.5 (0.3, 0.7) 1.5 (1.1, 2.5) 200* 0.3 (0.2, 0.5) 0.9 (0.6, 1.7) 200*
VLDL-TG, mmol/L 0.7 (0.4, 1.0) 2.2 (1.3, 3.2) 214* 0.9 (0.6, 1.2) 2.7 (2.1, 4.2) 200* 0.6 (0.3, 0.8) 1.6 (1.0, 2.6) 167*
sdLDL-C, mg/dL 37 (19) 57 (27) 54* 48 (19) 50 (24) 4 30 (14) 60 (27) 100*
RLPC, mmol/L 6 (4, 10) 20 (12, 35) 233* 8 (5, 12) 29 (19, 53) 263* 5 (4, 8) 16 (9, 26) 220*
ApoB, mg/L 960 (221) 1371 (256) 43* 1026 (214) 1372 (198) 34* 898 (210) 1371 (294) 53*
ApoB48, mg/dL 0.4 (0.2, 0.6) 0.8 (0.5, 1.6) 100* 0.4 (0.3, 0.6) 1.4 (1.0, 1.8) 250* 0.3 (0.2, 0.5) 0.7 (0.4, 1.1) 133*
Values are mean (SD) or median (interquartile range). *P0.001, †P0.01, ‡P0.05. P values were adjusted for age and family structure. Because of limited
sample availability insulin, sdLDL-C, RLPC, and ApoB48 were measured in 269 subjects.
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as medians and interquartile ranges. Spearman correlation
coefficients were calculated for BMI, WHR, glucose and insulin
levels, and the cholesterol synthesis and absorption markers. For
the comparisons among the NLR and FCH group, probability
values were adjusted for age, BMI, family structure by logistic
regression, using FCH status as dependent variable and age,
BMI, and the family identification number and the variable under
investigation as independent variables. A probability value less
than 0.05 was considered statistically significant and all calcula-
tions were performed using the STATA software package,
version 10.
Results
The characteristics of the 103 patients with FCH and the
240 NLR are presented in the study population at large, as
well as stratified by gender (Table 1). There was no
difference in the gender distribution among FCH patients
and their NLR, although the FCH group was significantly
older and had higher BMIs and WHRs (P0.05 for all
comparisons). FCH patients had higher glucose (P0.01)
and insulin (P0.001) levels and as expected, higher
levels of total cholesterol, triglycerides, non–HDL-C,
VLDL-C and VLDL-TG (P0.001, for all parameters) and
HDL-C levels were significantly lower. In addition, RLPC,
apoB and apoB48 (the intestinal apoB), were significantly
higher (P0.001, for all comparisons) in FCH as com-
pared to the NLR. There were interesting gender differ-
ences among FCH patients and the NLR. In women, FCH
was associated with 33% higher LDL-C levels and 100%
higher sdLDL-C levels (P0.001, for both comparisons),
whereas these difference were not observed in the men. As
mentioned above, apoB48 levels were higher in the FCH
group when compared to the NLR, however the percentile
difference observed in men was almost twice as high as the
difference seen in women (250% higher versus 133%).
Individual correlations between markers cholesterol
synthesis and absorption in relation to markers of obesity
and insulin resistance are presented in Table 2. In the
combined study groups, lathosterol and desmosterol levels
correlated (all at P0.001) with BMI and WHR and with
glucose and insulin levels. In addition, there was a small
inverse correlation for sitosterol with BMI and insulin
levels (both P0.05, Table 2). Supplemental Table I
(available online at http://atvb.ahajournals.org) provides
data showing a better correlation for lathosterol and
desmosterol with glucose levels and a less pronounced
correlation with insulin levels in the FCH patients com-
pared to the NLR. The nature of these correlations re-
mained the same in gender subgroups (data not shown).
We observed a strong correlation between both lathosterol
and desmosterol in relation to apoB, triglycerides, and
LDL-C (P0.001 for all), which appeared to be stronger in
women than in men (supplemental Table II). In addition,
apoB and LDL-C correlated with campesterol and sitosterol
in both men and women and with cholestanol in men only
(supplemental Table II).
The FCH phenotype was associated with increased
markers of cholesterol synthesis (Table 3). Lathosterol
levels were elevated by 51% (P0.001) in FCH, squalene
tended to be higher in FCH (6%, P0.125), however,
this effect was observed in women only (15%, P0.001)
and not in men. In addition, desmosterol levels were 54%
higher in female FCH patients (P0.001) and only 11%
higher in male FCH patients (P0.069) when compared to
their NLR counterparts. To account for the fact that plasma
sterols are mainly transported in the LDL and HDL
particles,34 values were also presented as ratio to total
cholesterol (/C). Although squalene concentrations were
increased in female FCH patients 15% (P0.001),
squalene/C levels were actually reduced in both male and
female FCH patients by 21% (P0.010) and 14%
(P0.050), respectively, independent of BMI. Desmos-
terol/C and lathosterol/C overall remained comparable to
the unadjusted values, desmosterol/C being elevated in
women by 24% (P0.002) and lathosterol/C in both men and
women by 17% (P0.013) and 22% (P0.001), respec-
tively. Adjusting the lathosterol and desmosterol associations
for BMI did not affect the level of significance of the sterol
markers when expressed in absolute terms, however the
associations were no longer significant when using the sterol
values normalized to total cholesterol.
Markers of cholesterol absorption in FCH patients and
NLR are presented in Table 4. With regard to these
markers there was evidence for a gender interaction. In
men with FCH, absolute concentrations of campesterol and
sitosterol tended to be elevated by 21% (P0.065), while
remaining constant in women. After adjusting for BMI, the
differences were significant (P0.012 and P0.027).
Normalized to total cholesterol, campesterol/C and sitos-
terol/C were no longer elevated in men and significantly
lower in women with FCH (26%, P0.003 and 25%,
P0.004, respectively). Absolute cholestanol concentra-
tions were not different in FCH, but cholestanol/C was
16% lower (P0.001) in both men and women with FCH
and independent of BMI.
Although we did not observe correlations between the
markers of synthesis and absorption when expressed in
absolute terms (data not show), there was a negative corre-
lation between lathosterol/C and campesterol/C in the NLR
(r0.271, P0.001) not observed in the FCH patients
(r0.156, P0.120). Furthermore, the lathosterol/campes-
terol ratio was 37% higher in FCH patients than in NLR, and
this was predominantly attributable to the elevations observed
in women (66%) rather than in men (19%) (Table 5).
Table 2. Correlations of the Cholesterol Synthesis and
Absorption Markers With BMI, WHR, Glucose, and Insulin in All
Subjects (n343)
BMI WHR Glucose Insulin
Squalene 0.062 0.059 0.013 0.011
Lathosterol 0.482* 0.471* 0.389* 0.336*
Desmosterol 0.337* 0.320* 0.360* 0.304*
Campesterol 0.082 0.081 0.076 0.074
Sitosterol 0.128† 0.030 0.074 0.148†
Cholestanol 0.063 0.032 0.013 0.110
Values represent Spearman Rank correlation coefficients. *P0.001 and
†P0.05.
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Discussion
Since the description and characterization of the FCH
phenotype more than 30 years ago,1 many studies have
been undertaken to uncover the mechanisms causing FCH.
Both the results of biochemical investigations as well as
the results from candidate gene studies and genome wide
scan studies have been of great interest, but the actual
cause of the elevated total cholesterol, triglycerides, and
apoB levels as well as the underlying genetic defect has
not yet been elucidated. This study shows that both men
and women with FCH have higher levels of the cholesterol
precursor lathosterol when compared to their NLR. Based
on these findings we hypothesize that patients with FCH
have an underlying defect in sterol metabolism resulting in
overproduction of lathosterol and cholesterol.
The higher sterol levels observed in the FCH may
suggest that this is the result of impaired plasma disposal
of these sterols or an impaired conversion to cholesterol.
Alternatively, lathosterol and desmosterol are both formed
from squalene, each via a different pathway (see Figure).
Although we found marginally higher levels of plasma
squalene (6%), this effect was predominantly attributable
to increased squalene levels in women (15%). When the
squalene levels were expressed as a ratio over total
cholesterol, we found them to be lower in both men and
women. The cholesterol precursor lathosterol was elevated in
men and women with FCH (both in absolute terms as well as
adjusted for total cholesterol), suggesting that there is either
enhanced conversion of squalene to lathosterol or increased
direct production of lathosterol in these patients. Although a
limitation of our study is that the design is cross-sectional and
does not establish causation, in FCH we find increased levels
of lathosterol which correlate with apoB, triglycerides and
LDL-C, suggesting that FCH is (partly) the result of an
imbalance in the cholesterol synthesis pathway and future
research should focus on regulators within this pathway.
In contrast to the markers of cholesterol synthesis, the
differences among FCH and NLR regarding the markers of
cholesterol absorption are less clear. Both campesterol and
sitosterol tended to be higher in FCH patients, but these
Table 3. Cholesterol Synthesis Markers, Expressed in Absolute Concentrations as Well as
Normalized to Total Cholesterol, in the Normolipidemic Relatives (NLR) and Patients With
Familial Combined Hyperlipidemia (FCH)
NLR FCH
% Difference
FCH vs NLR P Value†
BMI Adj.
P Value‡
Sterols expressed in mol/L
Squalene
Total 1.26 (0.37) 1.33 (0.43) 6 0.078 0.433
Men 1.36 (0.44) 1.31 (0.40) 4 0.706 0.355
Women 1.17 (0.27)* 1.35 (0.44) 15 0.001 0.011
Desmosterol
Total 1.6 (1.1, 2.4) 2.1 (1.6, 3.1) 31 0.001 0.018
Men 1.9 (1.3, 2.8) 2.1 (1.6, 3.3) 11 0.069 0.444
Women 1.3 (1.0, 1.9)* 2.0 (1.5, 3.1) 54 0.001 0.001
Lathosterol
Total 7.4 (3.1) 11.2 (4.0) 51 0.001 0.001
Men 8.3 (3.6) 11.9 (3.7) 43 0.001 0.006
Women 6.6 (2.4)* 10.7 (4.1) 62 0.001 0.001
Sterols expressed as 102
mmol/mol cholesterol
Squalene/C
Total 26.5 (8.9) 22.0 (7.4) 17 0.001 0.001
Men 27.1 (9.6) 21.4 (7.3) 21 0.010 0.007
Women 25.9 (8.1) 22.4 (7.6) 14 0.050 0.021
Desmosterol/C
Total 34 (24, 46) 36 (27, 52) 6 0.267 0.714
Men 39 (28, 54) 34 (25, 52) 13 0.821 0.319
Women 29 (22, 42)* 36 (28, 53) 24 0.029 0.290
Lathosterol/C
Total 150 (55) 179 (61) 19 0.001 0.155
Men 160 (59) 187 (64) 17 0.010 0.369
Women 142 (49)* 173 (59) 22 0.001 0.098
*Significantly different from men at P0.05 within the subgroup. †P values adjusted for age and family structure.
‡P values adjusted for age and family structure and BMI.
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findings were restricted to men and were only significant
when taking into account BMI. When the absorption
markers were expressed relative to total cholesterol, we
found significantly lower levels in women for campes-
terol/C and sitosterol/C. Cholestanol/C was lower in both
men and women. The question remains however whether
the association of FCH with lower values for the absorp-
tion markers over cholesterol is a true effect (ie, the result
of lower cholesterol absorption), or whether it is the result
of dividing a constant concentration of absorption markers
by a higher total cholesterol concentration caused by
increased cholesterol synthesis. Furthermore, it is known
that dietary intake of plant sterols can affect plasma
concentrations of campesterol and sitosterol.35 Because no
dietary information was collected, we cannot rule out that
FCH patients were consuming greater amounts of dietary
Table 4. Cholesterol Absorption Markers, Expressed in Absolute Concentrations as Well as
Normalized to Total Cholesterol, in the Normolipidemic Relatives (NLR) and Patients With
Familial Combined Hyperlipidemia (FCH)
NLR FCH
% Difference
FCH vs NLR P Value†
BMI Adj.
P Value‡
Sterols expressed in mol/L
Campesterol
Total 9.7 (7.1, 13.2) 11.0 (7.8, 15.3) 13 0.191 0.022
Men 10.2 (7.7, 14.2) 12.3 (9.7, 17.3) 21 0.065 0.012
Women 9.1 (6.8, 12.3)* 9.5 (7.1, 13.0)* 4 0.726 0.243
Sitosterol
Total 6.2 (4.7, 8.1) 7.1 (4.7, 10.1) 15 0.167 0.006
Men 6.2 (4.9, 8.3) 7.5 (5.5, 10.4) 21 0.131 0.027
Women 6.2 (4.6, 8.0) 6.1 (4.5, 9.5) 2 0.571 0.068
Cholestanol
Total 7.8 (2.8) 8.1 (3.0) 4 0.387 0.303
Men 8.3 (3.1) 8.3 (2.3) 0 0.912 0.887
Women 7.3 (2.4)* 7.9 (3.4) 8 0.180 0.125
Sterols expressed as 102
mmol/mol cholesterol
Campesterol/C
Total 203 (155, 264) 169 (135, 241) 17 0.011 0.302
Men 200 (152, 286) 181 (158, 273) 10 0.839 0.369
Women 207 (158, 259) 154 (113, 211)† 26 0.003 0.052
Sitosterol/C
Total 128 (98, 165) 109 (82, 152) 15 0.004 0.396
Men 121 (96, 157) 119 (86, 163) 2 0.347 0.710
Women 135 (100, 170) 101 (78, 148) 25 0.004 0.164
Cholestanol/C
Total 160 (53) 134 (48) 16 0.001 0.010
Men 162 (56) 135 (40) 17 0.030 0.067
Women 158 (50) 133 (53) 16 0.015 0.059
*Significantly different from men at P0.05 within the subgroup. †P values adjusted for age and family structure.
‡P values adjusted for age and family structure and BMI.
Table 5. Ratios of Lathosterol Over Campesterol in the Normolipidemic Relatives (NLR) and
Patients With Familial Combined Hyperlipidemia (FCH)
NLR FCH
% Difference
FCH vs NLR P Value†
BMI Adj.
P Value‡
Lathosterol/
campesterol ratio
Total 0.71 (0.43, 1.11) 0.97 (0.67, 1.42) 37 0.001 0.194
Men 0.77 (0.39, 1.27) 0.92 (0.71, 1.18) 19 0.097 0.305
Women 0.62 (0.44, 1.01)* 1.03 (0.66, 1.71)* 66 0.001 0.018
*Significantly different from men at P0.05 within the subgroup. †P values adjusted for age and family structure.
‡P values adjusted for age and family structure and BMI.
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plant sterol margarines and other sterols as compared to
controls. Finally, even though we noted elevated levels of
apoB48 in FCH patients, these elevations are likely a
reflection of delayed clearance of intestinal remnant li-
poproteins as previously described in FCH,36 rather than
attributable to increased absorption, and overall, these
findings suggest that FCH is not associated with altered
cholesterol absorption.
Previous studies suggest a central role for fat mass in the
onset of FCH.37 In agreement with this concept, we found
associations indicating that there is an interaction between
plasma sterols and BMI which may play a central role in
the onset of FCH. The relationship between obesity and
cholesterol production is not straightforward because more
fat mass does not always cause excess cholesterol produc-
tion. This concept was illustrated by a recent study from
our laboratory in 19 severely obese women undergoing
bypass surgery, showing a markedly reduction in fat mass
without a significant reduction in total cholesterol levels.38
A possible mechanism linking plasma sterols to fat metab-
olism may come from the demonstration that sterol inter-
mediates from the cholesterol synthesis pathway, espe-
cially desmosterol, act as liver x receptor (LXR) ligands.39
LXR stimulates hepatic triglyceride synthesis and fat
storage and has been described as a master regulator of fat
metabolism.40 Further studies are necessary to determine a
possible interaction between LXR, desmosterol and the
other plasma sterols in cases with FCH versus controls.
We have performed extensive characterization of the
lipid and apolipoprotein profiles in FCH patients and their
NLR, as well as in subgroups of men and women, and
found that within the FCH group LDL-C and sdLDL-C
were elevated in women only. This may suggest that in
female FCH patients there is even greater cholesterol
synthesis than in male FCH patients. In agreement, the
cholesterol synthesis data also suggest that there are
gender specific mechanisms associated with FCH. Al-
though lathosterol was elevated in both male and female
FCH patients, the effect seemed to be more prominent in
women than in men (62% versus 42%). The other choles-
terol precursors, squalene and desmosterol, were signifi-
cantly higher (15% and 54%, respectively) in FCH women
while remaining constant in men. These increases observed
in FCH women were attributable to the fact that in the
NLR group the women had lower sterol levels than the
men. This was especially true for desmosterol. In women,
desmosterol levels were higher in the FCH compared to the
NLR group, but similar to the levels seen in the FCH men.
To speculate on a possible underlying mechanism, recent
studies demonstrate that the enzyme responsible for the
conversion of desmosterol to cholesterol (ie, 24-
dehydrocholesterol reductase, DHCR24 also known as
Seladin-1), is activated by estrogens.41 In theory the
activation of the DHCR24 by estrogens may be reduced in
women with FCH, resulting in elevated desmosterol levels.
In support of this concept, a post hoc analysis in this study
population revealed that desmosterol levels (but not
squalene levels) were significantly higher in postmeno-
pausal women when compared to premenopausal women
(57% higher, P0.001).
To our knowledge this is the second study to measure
synthesis and absorption markers in FCH patients. Previ-
ously, Garcia-Otin and colleagues measured cholesterol
synthesis and absorption markers among autosomal dom-
inant hypercholesterolemia (ADH) patients, including 31
patients with familial hypercholesterolemia and 38 patients
with FCH.42 In contrast to our study, which was designed
to gain insight into the mechanism underlying FCH, the
primary objective of the Garcia-Otin group was to use
these markers to differentiate between the different forms
of ADH. They noted that the campesterol/C and sitosterol/C
ratios were lower in the FCH patients when compared to
controls, which is in line with our cholesterol adjusted
data, but they observed no differences for the lathosterol/C
ratio, suggesting that alterations in absorption markers
were associated with FCH. Their study, however, was
conducted in a FCH group consisting of predominantly
men (27 versus 11 women), and limited numbers prevented
them from analyzing subgroups. Because this is the second
study to measure synthesis and absorption markers in a
FCH population, replication of these findings is necessary
in different study populations, preferably using the same
standardized diagnostic criteria for FCH.27
Finally, we would like to speculate on possible novel
candidate genes, taking into account our findings that the
FCH phenotype was associated with elevated cholesterol
synthesis markers. USF1 has been suggested to be the most
important candidate gene for FCH.17 However, in these
families USF1 was not a major gene for FCH, but rather a
modifier gene contributing to related lipid traits.43 Re-
cently, a whole genome study mapped all the target regions
of USF1 and identified multiple regions involved in the
Figure. An overview of the cholesterol synthesis from
squalene. Intermediate reactions from lanosterol to desmos-
terol and lathosterol in the Bloch pathway and Kandutsch–
Russell pathway, respectively, are not shown. Sterol-C5-
desaturase-like (SC5DL) converts lathosterol into
7-dehydrocholesterol. The 24-dehydrocholesterol reductase
(DHCR24) catalyzes the reduction of the -24 double bond of
sterol intermediates in the Bloch pathway forming a sterol
which is part of the Kandutsch–Russell pathway. DHCR24
also catalyzes the formation of cholesterol from desmosterol.
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lipid metabolism,44 including a number of vital genes in
the synthesis of cholesterol summarized in supplemental
Table III. Of these genes, sterol-C5-desaturase-like
(SC5DL) plays a crucial role in the formation of choles-
terol from lathosterol and the (earlier mentioned) DHCR24
is involved in many steps of the synthesis of cholesterol,
one of which is the conversion of desmosterol to choles-
terol. Our findings of elevated lathosterol in both men and
women with FCH, and the association of lathosterol with
LDL-C, triglycerides, and apoB in our entire study popu-
lation, raises the possibility that the SC5DL gene is a
candidate gene for FCH. In addition, when the chromo-
some 1 data were reanalyzed in the Dutch population, it
revealed that 1p31 was strongly linked to elevated apoB
levels.45 The authors hypothesized that the nearby leptin
receptor (LEPR) gene was involved, but the data proved to
be negative.45 Although speculative, the DHCR24 gene is
also located in this region (Table 4) and based on our
findings of increased desmosterol in women and the
association of desmosterol with apoB levels, we hypothe-
size that alterations in this gene may cause elevated apoB
rather than the LEPR gene. Future studies, sequencing the
SC5DL as well as the DHCR24 genes in FCH patients,
appear to be warranted.
In conclusion, our study indicates that FCH patients have
alterations in the cholesterol synthesis pathway, resulting in
higher levels of lathosterol (and additionally desmosterol in
women). In the cholesterol synthesis pathway there are 2
enzymes that warrant further investigation: SC5DL and
DHCR24. The genes for these enzymes are located in exactly
those chromosomal regions previous linked to FCH in ge-
nome wide scans, and code for the key enzymes involved in
the metabolism of lathosterol and desmosterol, the sterols we
found to be elevated in FCH patients. Our data indicate that
FCH patients appear to have enhanced conversion of
squalene to lathosterol, and further examination of the
SC5DL and DHCR24 genes and their gene products appear to
be justified and may ultimately lead us to a precise under-
standing of the defects underlying FCH.
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Supplement Material. 
 
 
 
 
Supplemental Table I. Correlations of the cholesterol synthesis and absorption markers with 
Glucose and Insulin in NRL and FCH patients. 
 NLR  FCH 
 Glucose Insulin  Glucose Insulin 
Squalene 0.060 -0.031  -0.152 -0.049 
Lathosterol 0.261* 0.217†  0.456* 0.112 
Desmosterol 0.269* 0.239†  0.382* 0.187 
Campesterol -0.001 -0.150‡  0.087 -0.145 
Sitosterol 0.026 -0.225†  0.008 -0.241‡ 
Cholestanol 0.010 -0.132  -0.067 0.070 
Values represent Spearman Rank correlation coefficients. *p<0.001, †p<0.01 and ‡p<0.05. 
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Supplemental Table II. Correlations of the cholesterol synthesis and absorption 
markers with apoB, triglycerides and LDL-C in all subjects (n=343) and by 
gender. 
 ApoB Triglycerides LDL-C 
Squalene    
Total  0.001 -0.010 0.038 
Men  -0.003 -0.151 0.126 
Women -0.038 0.046 -0.042 
Lathosterol    
Total  0.577* 0.534* 0.385* 
Men  0.484* 0.514* 0.209‡ 
Women 0.610* 0.498* 0.505* 
Desmosterol    
Total  0.452* 0.383* 0.407* 
Men  0.236† 0.236† 0.231† 
Women 0.550* 0.430* 0.530* 
Campesterol    
Total  0.270* 0.010 0.248* 
Men  0.326* -0.033 0.276* 
Women 0.201† -0.005 0.230† 
Sitosterol    
Total  0.275* -0.038 0.267* 
Men  0.393* 0.000 0.334* 
Women 0.172‡ -0.098 0.212† 
Cholestanol    
Total  0.153† -0.040 0.192* 
Men  0.212† -0.055 0.265† 
Women 0.066 -0.086 0.127 
Values represent Spearman Rank correlation coefficients. *p<0.001, †p<0.01 and 
‡p<0.05. 
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 Supplemental Table III. Key enzymes in the cholesterol metabolism pathway of which the genes posses a USF1 
binding site 
Gene  Chromoso
me 
Protein Metabolic Function 
MVK 12q24 mevalonate kinase Converts Mevalonic acid into mevalonate 5-phosphate. 
PMVK 1q22 phosphomevalonate kinase Converts mevalonate 5-phosphate into mevalonate 5-
diphosphate. 
SC5DL 11q23.3 sterol-C5-desaturase-like Converts of lathosterol into 7-dehydrocholesterol. 
DHCR24 1p33-p31.1 24-dehydrocholesterol reductase 
(also known as Seladin-1) 
Catalyzes the reduction of the delta-24 double bond of 
sterol intermediates during cholesterol biosynthesis.  
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